a b s t r a c t Mammalian brain expresses multiple nicotinic acetylcholine receptor (nAChR) subtypes that differ in subunit composition, sites of expression and pharmacological and functional properties. Among known subtypes of receptors, a4b2* and a6b2*-nAChR have the highest affinity for nicotine (where * indicates possibility of other subunits). The a4b2*-nAChRs are widely distributed, while a6b2*-nAChR are restricted to a few regions. Both subtypes modulate release of dopamine from the dopaminergic neurons of the mesoaccumbens pathway thought to be essential for reward and addiction. a4b2*-nAChR also modulate GABA release in these areas.
Introduction
Dependence on nicotine partially underlies the difficulty encountered in smoking cessation. Currently available smoking cessation aids (nicotine replacement, bupropion or varenicline treatment) are helpful for a subset of the population, with variable relapse prevention (Lerman et al., 2007; De Biasi and Salas, 2008) . There is a need for treatments with improved effectiveness, relapse prevention, tolerability, and safety.
Nicotine elicits physiological and behavioral effects through actions as an agonist and/or desensitizer at nicotinic acetylcholine receptors (nAChRs). nAChRs in brain exist as pentamers made up of the a2-7, and b2-4 subunits. Some nAChRs are homomers (a7), but most are heteromers (b2 or b4 in combination with a subunits) (Gotti et al., 2006) . a4b2*-nAChRs, which comprise the most widely expressed high-affinity subtypes, play a major role in modulating the effects of smoked nicotine (Mameli-Engvall et al., 2006; Keath et al., 2007) . Some a4b2*-nAChRs are upregulated by chronic exposure to nicotine (Flores et al., 1992; McCallum et al., 2006; Nashmi et al., 2007; Lester et al., 2009 ).
The a4a6b3b2 nAChR has the highest sensitivity for nicotine of any subtypes studied to date (Salminen et al., 2007) . In contrast to the widespread distribution of a4b2*-nAChR, a6b2*-nAChRs have a restricted distribution, localized primarily to dopamine (DA) neurons, noradrenergic neurons, and visual tracts (Whiteaker et al., 2000b; Champtiaux et al., 2002 Champtiaux et al., , 2003 Quik et al., 2003; Drenan et al., 2008) . Both of these b2*-nAChR subtypes are important regulators of DA release in the nucleus accumbens, which participates in the rewarding effects of nicotine (Exley et al., 2008) . a6b2*-nAChRs in mesoaccumbens dopaminergic neurons may be necessary for nicotine self-administration (Pons et al., 2008) . Interestingly, a6b2*-nAChRs, despite their high sensitivity to nicotine, are upregulated at comparatively high nicotine concentrations when expressed in HEK cells (Tumkosit et al., 2006) , while they are downregulated following chronic nicotine treatment in rats and mice (Lai et al., 2005; Perry et al., 2007; Perez et al., 2008) .
Whole genome scans in humans have detected genetic associations between a6-nAChR subunit genes and aspects of human smoking. The CHRNA6/B3 gene cluster has significant associations with subjective responses to nicotine (Zeiger et al., 2008) , tobacco dependence, and number of quit attempts (Hoft et al., 2008) . These associations may suggest that a6*-nAChRs could be an important target for nicotine. nAChR subtype selective compounds will become pharmacological tools to help identify how various subtypes affect the acquisition and maintenance of addiction, as well as which subtypes are good targets for smoking cessation therapy. Selective compounds may enable therapies to be tailored to individuals by combining genetic association data with appropriate smoking cessation aids (Ho and Tyndale, 2007) . Based on knowledge gained using nAChR subunit null mutant mice and various selective agonists and antagonists, we have devised a battery of assays to assess binding affinity, functional potency and efficacy at four subtypes of nAChR (a4b2*, a6b2*, a7 and a3b4*). Gain-of-function a4L9 0 A (Tapper et al., 2007) and a6L9 0 S (Drenan et al., 2008) mice have been developed to evaluate selective activation of a4b2* or a6b2*-nAChR in vivo. We have assessed the effects of structural modifications of nicotine that may improve selectivity for a4b2* and/or a6b2*-nAChRs. 
Methods

Materials
Compound synthesis
Compounds 1 (RJR2429, TC2429, (AE)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2] octane), 3 (TC1698, 2-(pyridine-3-yl)-1-azabicyclo[3.2.2]nonane), 6 (TC6951, (4S)-2-(5-phenylpyridin-3-yl)quinuclidine) and 7 (TC2242, 4-(5-(quinuclidin-2-yl)pyridin-3-yloxy)benzonitrile) were synthesized using previously published methods (Bhatti et al., 2008 compounds 3, 6, 26, and 29, respectively) . Varenicline was synthesized by the methods of Coe et al. (2005) and Compound 8 (RJR2403, TC2403, (E)-N-methyl-4-(3-pyridinyl)-3-butene-1-amine) following the methods of Bencherif et al. (1996) . For other compounds: Compound 2: (7-(pyridin-3-yl)-1-azabicyclo[2.2.1]heptane) Bencherif, Merouane; Miller, Craig Harrison; Hawkins, Gregory D.; Bhatti, Balwinder S., preparation of pyridinyl substituted azabicyclic compounds for use in pharmaceutical compositions which effect dopamine release, U.S. Pat. Appl. US2004220214. Compound 4: (1-aza-2-(3-pyridinyl)-tricyclo [3.3.1.13,7] decane) Bencherif, Merouane; Lippiello, Patrick Michael; Crooks, Peter Anthony; Park, Haeil; Bhatti, Balwinder Singh; Caldwell, William Scott; Dull, Gary Maurice, preparation of azatricyclo [3.3.1.13,7] decanes and related compounds as nicotinic antagonists, PCT Int. Appl. WO9951602.Compound 5: (2-(pyridin-3-ylmethyl)quinuclidine) Schmitt, Jeffrey Daniel; Crooks, Peter Anthony; Dull, Gary Maurice, preparation of pyridyl-bridgehead derivatives and their analogs, pharmaceutical compositions and methods for use, US Patent 6,432,975. Compound 9: ((E)-N-methyl-5-(5-(phenylethynyl)pyridin-3-yl)pent-4-en-2-amine) was prepared from known 3-bromo-5-(2-phenylethynyl)-pyridine (Agejas-Chicharro, Francisco Javier; Dressman, Bruce Anthony; Gutierrez Sanfeliciano, Sonia; Henry, Steven Scott; Martinez Perez, Jose Antonio; Massey, Steven Marc; Monn, James Allen; Zia-Ebrahimi, Mohammad Sadegh, preparation of pyridines as mGlu5 receptor antagonists, PCT Int. Appl. WO2005094822), according to the general methods cited in: Caldwell, William Scott; Dull, Gary Maurice; Dobson, Grayland, 3-pyridinyl compounds. US 6,603,011. Compound 10 ((1R,5S)-3-(5-bromopyridin-3-yl)-8-methyl-8-azabicyclo[3.2.1]oct-3-ene) was prepared analogously to compounds reported previously (Gohlke et al., 2003) . Compound 11 (2-((5-chloropyridin-3-yloxy)methyl)quinuclidine) was prepared as described previously (Zhao et al., 2002) .
Animals
All animal procedures were in accordance with the guidelines of the National Institutes of Health. Mice of the C57BL/6J strain 60e90 days of age, used for this study were bred and maintained at the Institute for Behavioral Genetics, University of Colorado, Boulder, CO. After weaning at 25 days of age, same sex littermates were housed 5 to a cage with free access to food (Teklad Rodent Diet, Harlan, Madison, WI) and water, with a 12-h light/dark cycle at 22 C. Mice of the a4 subunit null mutant mice (originally from Dr. John Drago), were bred and maintained as above and genotyped as previously described (Salminen et al., 2004) . Animal care and experimental procedures for these mice were in accordance with the guidelines and approval of the Animal Care and Utilization Committee of the University of Colorado, Boulder, CO.
Hypersensitive a4L9 0 A knock-in mice (Tapper et al., 2007) and a6L9 0 S (Drenan et al., 2008 ) transgenic mice were bred and maintained at the California Institute of Technology, Pasadena, CA. Animal care and experimental procedures with these mice were approved by the California Institute of Technology Animal Care and Use Committee.
Tissue preparation for binding studies
The methods of Marks et al. (1998 Marks et al. ( , 2006 were followed for preparation of brain membranes in hypotonic buffer. These membrane preparations were stored as pellets under buffer at À70 C or used immediately for striatum (ST) and superior colliculus (SC)) were pooled and homogenized in hypertonic (2Â) buffer (NaCl, 288 mM; KCl, 3 mM; CaCl 2 , 4 mM; MgSO 4 , 2 mM; HEPES, 40 mM; pH ¼ 7.5) and then incubated with PMSF (1 mM) at 22 C for 15 min to inactivate serine proteases. After centrifugation (20,000 Â g for 15 min at 4 C), the pellet was resuspended in hypotonic buffer and re-centrifuged twice. The final pellet was resuspended in distilled water and used without freezing.
[ 125 I]-a-Bungarotoxin binding
A modification of previously published methods was used (Marks et al., 1998 ]-a-Btx binding were added to triplicate wells; nonspecific binding was determined from wells to which a-cobratoxin (100 nM) was added. After incubation for 2.5 h at room temperature, samples were diluted with 0.5 ml binding buffer and incubated an additional 0.5 h. This dilution step decreases non-specific binding. Reaction was terminated by filtration onto glass fiber filters (MFS GB top layer, Gelman A/E bottom layer, both soaked in binding buffer containing 0.5% polyethylenimine) using an Inotech Cell Harvester (Inotech, Rockville, MD). Samples were washed 6 times with ice-cold binding buffer and bound [
125 I]-aBtx was determined by counting at 60% efficiency in a 1450 MicroBeta Trilux scintillation counter after addition of Optiphase SuperMix scintillation cocktail (150 ml/ sample) (Perkin Elmer Life Sciences-Wallac Oy, Turku, Finland). ]-epibatidine binding was determined using methods previously described (Marks et al.,1998; Whiteaker et al., 2000a) The methods of Salminen et al. (2005 Salminen et al. ( , 2007 were followed. Membrane samples (40e50 mg protein) from pooled olfactory tubercle, striatum and superior colliculus were incubated with 0.5 nM [
125 I]-a-CtxMII in 30 ml binding buffer supplemented with BSA (0.1%), EDTA (5 mM), EGTA (5 mM), and the protease inhibitors, aprotinin, leupeptin and pepstatin A (10 mg/ml each). Various concentrations of a compound to be tested for inhibition were added to triplicate wells. Non-specific binding was determined from wells to which 1 nM epibatidine was added. Binding reactions were incubated at 22 C for 2 h, then diluted with 1 ml of buffer containing 0.1% BSA and incubated 4 min longer. Reactions were terminated by filtration onto a single sheet of GF/F filter paper (Whatman, Clifton, NJ) treated with 5% nonfat dry milk for 30 min. Samples were washed four times with ice-cold buffer containing BSA (0.1%). Bound ligand was determined by beta counting as above. It has been demonstrated that this concentration of a-CtxMII measures a6*-nAChR in mouse dopaminergic and visual tractregions as no binding remains there in the a6 null mutant mouse (Champtiaux et al., 2002) , and, in addition, the a3 null mutation has no effect on a-CtxMII binding in these regions (Whiteaker et al., 2002) .
Membrane binding data analysis
After subtraction of non-specific binding, inhibition of binding was analyzed by using a one-site fit to the inhibition equation (B¼B o (Whiteaker et al., 2000a) . K i values were calculated from IC 50 values using the equation (K i ¼ IC 50 /(1þ(L/K D )). Means AE sem from three to four experiments are reported.
Synaptosomal preparation
Regions of interest were dissected from fresh mouse brains and homogenized in ice-cold isotonic sucrose (0.32 M) buffered with HEPES (5 mM, pH 7.5). The suspension was centrifuged at 12,000 Â g for 20 min and the pellet resuspended in the appropriate uptake buffer (Salminen et al., 2007; Grady et al., 2001; Marks et al., 2007) and used immediately.
[ 3 H]-Dopamine uptake and release
Release methods of Salminen et al. (2004 Salminen et al. ( , 2007 were used. Briefly, the crude synaptosomal pellet from striatal tissue was resuspended in dopamine uptake buffer (NaCl, 128 mM; KCl, 2.4 mM; CaCl 2 , 3.2 mM; MgSO 4 , 1.2 mM; KH 2 PO 4 , 1.2 mM; HEPES, 25 mM; pH 7.5; glucose, 10 mM; ascorbic acid, 1 mM; pargyline, 0.01 mM) at 1.6 ml/ tissue from one mouse. Synaptosomes were incubated at 37 C for 10 min before addition of [ 3 H]DA at 1 mCi for every 0.2 ml (w100 nM), and the incubation continued for another 5 min. Subsequently, aliquots of the suspension (80 ml) were distributed onto filters and perfused at room temperature with uptake buffer containing 0.1% BSA, nomifensine (1 mM), to prevent re-uptake of dopamine, and atropine (1 mM), to prevent any possible activation of muscarinic acetylcholine receptors, at 0.7 ml/min for 10 min before stimulation with agonist for 20 s. Selected aliquots were perfused with a-CtxMII (50nM) for the last 5 min of the wash period, immediately before stimulation. This concentration of a-CtxMII is sufficient to inhibit all a6b2*-nAChR forms present in mouse striatum (Salminen et al., 2007) . Fractions (w0.1 ml) were collected every 10s into 96-well plates using a Gilson F204 fraction collector (Middleton WI) for 3 min after the 10 min washout. After addition of 0.15 ml of Optiphase SuperMix scintillation cocktail, radioactivity was determined in a 1450 MicroBeta Trilux counter (Perkin Elmer Life Sciences e Wallac Oy, Turku, Finland).
[
3 H]-ACh uptake and release
Release methods of Grady et al. (2001) were followed with minor modifications. Briefly, the crude synaptosomal pellet from IPN tissue was resuspended in choline uptake buffer (NaCl, 128 mM; KCl, 2.4 mM; CaCl 2 , 3.2 mM; MgSO 4 , 1.2 mM; KH 2 PO 4 , 1.2 mM; HEPES, 25 mM; pH 7.5; glucose, 10 mM; 0.1% BSA) at 0.1 ml/mouse. After the addition of [ 3 H]choline at 2 mCi for every 0.1 ml (w300 nM), the suspension was incubated at 37 C for 30 min. Then, aliquots (20 ml) were distributed onto filters on the perfusion system at room temperature and perfused for 10 min at 0.7 ml/min with choline uptake buffer containing atropine (1 mM) before stimulation by agonist for 20 s. Collection of fractions and determination of radioactivity were as for dopamine release.
2.12.
86 Rb þ efflux
Nicotine-stimulated 86 Rb þ efflux from synaptosomes was investigated using the methods of Marks et al. (1999 Marks et al. ( , 2007 with minor modifications. Briefly, Crude synaptosomes prepared from thalamus were resuspended in uptake buffer (NaCl, 140 mM; KCl, 1.5 mM; CaCl 2 , 2 mM; MgSO 4 , 1 mM; HEPES, 25 mM; pH 7.5; glucose, 20 mM) (350 ml/mouse thalamus). Aliquots (25 ml) of the suspension were added to 10 ml of uptake buffer containing 4 mCi 86 Rb þ and incubated at room temperature for 30 min.
The whole sample was then collected onto filter paper (Type AE, Gelman, Ann Arbor, MI), rinsed once with 0.5 ml of uptake buffer, transferred to the perfusion apparatus, and perfused with buffer (NaCl,135 mM; CsCl, 5 mM; KCl,1.5 mM; CaCl 2 , 2 mM; MgSO 4 , 1 mM; HEPES, 25 mM; pH 7.5; glucose, 20 mM; tetrodotoxin, 50 nM; atropine 1 mM;
BSA 0.1%) at 2.5 ml/min for 5 min before data collection began. Stimulation by agonist was for 5s. Effluent was pumped through a 200 ml Cherenkov cell in a b-Ram HPLC detector (IN/US Systems, Tampa, FL) to continuously monitor radioactivity.
Synaptosomal function data analysis
All synaptosomal function assays were calculated as counts exceeding basal release determined from samples immediately preceding and following stimulation (Grady et al., 2001; Salminen et al., 2004; Marks et al., 1999 [An] is the concentration of antagonist) using the nonlinear least squares algorithm in SigmaPlot 5.0 (Jandel Scientific, San Rafael, CA). The errors for the EC 50 , IC 50 and efficacy (as maximum activity expressed as % nicotine) are errors generated by the least-squares computational algorithm in SigmaPlot termed "sem". This "sem" reflects error of the curve fit for the entire data set rather than an sem calculated from independent determinations of these parameters.
2.14. Current recordings from GH4C1 cells GH4C1, a stable cell line expressing the ha7-nAChR subunit, was used to measure whole-cell currents (see Dunlop et al., 2007 and Supplementary Fig. 1 ). After removal from the incubator, cells were washed twice with extracellular recording medium (NaCl, 130 mM; KCl, 5 mM; CaCl 2 , 2 mM; MgCl 2 , 2mM; glucose, 25 mM; HEPES, 10 mM, pH 7.4) and placed into a 48 channel Dynaflow chip (Cellectricon, Inc). Chips were placed on the Dynaflow stage of an inverted Zeiss microscope at room temperature. Borosilicate electrodes were filled with: Trisphosphate dibasic, 110 mM; Tris-base, 28 mM; EGTA, 11 mM; MgCl 2 , 2 mM; CaCl 2 , 0.5 mM; NaATP 4 mM, pH 7.25 and had resistance of 2e5 MU. Currents were recorded with Axopatch 700A amplifier, filtered at 1 kHz, and sampled at 5 kHz. On average, the whole-cell recording stabilized within <5 min. Responses were evoked by moving the cell in front of the agonist-containing channel for 1 s, and 30 s washout periods were used between applications. With this method, solution exchange occurs within 10 msec.
Electrophysiological data analysis
Data were fit to a single Hill equation using Prism 5 software. Data are expressed as mean AE SEM with of 4 independent measurements. Measurements of steady state current would result in EC 50 values shifted to the left by 10-fold or more approaching K i values for binding (see Supplemental Fig. 1 ). We used peak current measurements for data presented in this paper as most likely to represent activation EC 50 values comparable to those measured in our synaptosomal release and efflux assays.
Hypothermia and locomotor activity measurements
The methods of Tapper et al. (2007) were followed to measure the hypothermic effect of selected compounds. a4L9 0 A knock-in mice were used to isolate effects on a4b2*-nAChR subtypes as, in these mice, the dose required to elicit nicotine-induced hypothermia (0.01 mg/kg) is below doses that affect other subtypes as shown by a lack of effect of this dose in wild-type mice (Tapper et al., 2007) . Briefly, mice were injected ip with saline, low dose nicotine (0.01 mg/kg), selected compound (agonists), or selected compound (antagonist) followed by low dose nicotine 8 min later, and body temperature was recorded in the home cage via previously implanted telemetry probes (Vital View PDT-4000 from Respironics). The maximum change in temperature within 40 min of injection was recorded.
a6L9 0 S transgenic mice were used to isolate effects on a6b2*-nAChR subtypes with measurements of locomotor effects. Doses of nicotine (0.1 mg/kg) that do not affect wild-type mice have marked effects in these transgenic a6 mice (Drenan et al. (2008) . Briefly, baseline horizontal locomotor activity was measured in an infrared photobeam activity cage (San Diego Instruments, San Diego, CA) for 8 min before injection of either saline, low dose nicotine (0.1 mg/kg), selected compound (agonist), or selected compound (antagonist) followed by low dose nicotine 8 min later. Activity was then measured for an additional 30 min.
Results
This report incorporates two major themes: 1) We describe a battery of assays to assess the selectivity and activity of potential nicotinic compounds in vitro and in vivo. 2) We apply these assays to evaluate a series of potential nicotinic compounds in order to provide new data on nAChR subtype selectivity and to establish a structure-activity relationship (SAR) framework for assessing improved selectivity. The structures of the compounds tested in the current study are shown in Fig. 1 . ]-a-CtxMII binding, a selective ligand for a3b2* and a6b2* to mouse membranes from combined regions, striatum (ST), olfactory tubercles (OT), and superior colliculus (SC), which are all relatively high in the a6b2*-nAChR subtype and low in a3b2* (Salminen et al., 2005) . The K i for Compound 1 at this site is 1.14 nM.
Binding assays
Functional assays
The affinity measurements above provide some information on the interaction of ligands with these receptor subtypes, but give no indication of their functional activity. Fig. 3 presents functional data from appropriate biochemical (Fig. 3A , B, C) or electrophysiological ( Fig. 3D ) assays for each of the four nAChR subtypes, again using Compound 1 for illustration. For the data in panels A, B and C, functional responses were measured using mouse brain synaptosomes. The activity of a concentration of nicotine, maximal for each assay and assessed in the same assays, is also shown and has been used to estimate relative efficacy. EC 50 values were determined by fits to the Hill equation or, for biphasic curves, to two MichaeliseMenton equations.
Panel A of Previous data show that the higher agonist-sensitivity (HS) component also has higher sensitivity to block by DHbE (2 mM) (Marks et al., 1999) . We therefore isolated the DHbE-sensitive portion by subtracting the responses in the presence of DHbE from the total responses; the inset shows the calculated HS a4b2* responses.
The EC 50 value for this HS form is assessed from either this plot of the DHbE-sensitive component or by the higher-affinity portion of the biphasic plot. The lower sensitivity (LS) form is assessed from the curve with DHbE present and by the component of the concentration-response curve elicited by higher agonist concentrations. Compound 1 is a partial agonist at both the HS and LS forms with efficacies of 31% and 29% relative to the test concentrations of nicotine, respectively. Corresponding EC 50 values are 0.043 mM and 5.5 mM, much lower than those reported for nicotine [1.4 mM and 130 mM (Marks et al., 1999)] . Panel B of Fig. 3 shows results of the Compound 1 stimulated release of [ 3 H]-DA from mouse striatal synaptosomes. The three plots represent total release mediated by a combination of various b2*-subtypes, the portion resistant to inhibition by 50 nM a-CtxMII (virtually all HS form of a4b2* as the highest concentration assessed was 0.3 mM), and the difference which represents the portion sensitive to a-CtxMII (a6b2*) (Champtiaux et al., 2002 (Champtiaux et al., , 2003 Salminen et al., 2004) . Compound 1 is a partial agonist for the a-CtxMII-resistant (a4b2*) component with an efficacy 28% that of nicotine and an EC 50 value of 0.034 mM. In contrast, Compound 1 is a full agonist at the a-CtxMII-sensitive (a6b2*) component with an efficacy 109% that of nicotine and an EC 50 value of 0.0074 mM. The EC 50 values for both components are considerably lower than the corresponding values for nicotine [1.6 mM and 0.77 mM, respectively (Salminen et al., 2004) ].
Panel C of Fig. 4 shows the Compound 1-stimulated release of [
3 H]-ACh from mouse IPN synaptosomes, an assay that measures function of the a3b4*-nAChR subtype (Grady et al., 2001 ).
Compound 1 is a full agonist in this assay with a maximal response 106% that of nicotine and an EC 50 value of 0.43 mM, which is significantly lower than the EC 50 value for nicotine (64 mM, Grady et al., 2001 ) but substantially higher than that for HS a4b2*-or a6b2*-nAChR mediated responses.
Responses mediated by a7-nAChRs are more reliably measured by electrophysiology in transfected cell lines than by biochemical assays in mouse brain synaptosomes. Panel D of Fig. 4 shows data for peak whole-cell current evoked from patch-clamped GH4C1 cells expressing rat a7-nAChR. These data are expressed as % maximal ACh response. In comparison to ACh, nicotine was a full agonist for this activity (data not shown; 100% max at 200 mM). Compound 1 is also a nearly full agonist in this assay with a maximal response 89% that of nicotine. The EC 50 value of 0.66 mM was the highest of the four responses measured.
Screening of compounds
Each of the compounds represented in Fig. 1 was assayed for each of the measures illustrated in Figs. 2 and 3, respectively. K i values for inhibition of binding of these compounds are compiled in Table 1 . Fig. 4A presents these affinity values on log molar scales, in a plot that emphasizes each compound's rank order for each of the four subtypes. Most of the compounds evaluated had higher affinity for the a4b2*-nAChRs relative to the other subtypes, as is typical for most reported nicotinic ligands. For function (assays in Fig. 3 ), all compounds were initially screened for agonist activity. Several compounds had no agonist activity; and were tested for antagonist activity as measured by the inhibition of nicotine-stimulated responses, and K i values determined. The data on functional activity are compiled in Tables 2 and 3 and also represented graphically, as potency values (EC 50 or K i ) in Fig. 4B and efficacy relative to nicotine (as a percentage) in Fig. 4C . For this representation, a fully efficacious compound has 100% maximum activity as compared to the activity of nicotine, while an antagonist that fully blocks the effect of nicotine is plotted at À100%. Several compounds have partial activity (between 0 and 100) while a few are more efficacious than nicotine (over 100). A value of 0 indicates that no agonist or antagonist activity was detected. In addition to compounds 1e11, values for a number of common nicotinic compounds as well as varenicline are presented for comparison in Fig. 4A , B and C (see also Tables 1e3 for nicotine and varenicline).
a4b2*-nAChR-mediated responses
From the assays shown in panels A and B of Fig. 3 (Fig. 5A) . The mean ratio of the points (0.97 AE 0.14) does not differ from 1. The accuracy of these methods with a limited number of replicates appears adequate to ascertain functional potency within a w3e10-fold difference. For the purpose of identifying a compound useful for differentially activating or inhibiting subtypes of nAChRs, this level of accuracy should suffice.
Functional responses mediated by a4b2*-nAChR measured within the series of compounds shown in Fig. 1 reveal that only four of the eleven compounds (including Compound 1) are agonists (see Fig. 4C ). Compound 8 is more efficacious than nicotine, Compound 8 displays no measurable activity on a-CtxMII-sensitive DA release. Interestingly, a6b2*-nAChR appear to be activated by lower concentrations of many agonists than a4b2*-nAChR (see Fig. 4B and Table 2 ) even though these same agonists have higher affinity for a4b2* sites in binding assays (see Fig. 4A and Table 1 ). Comparing data in Fig. 4A and B, this pattern, where a compound has higher affinity for a4b2*-nAChR than a6b2*-nAChR for binding, but lower or equal potency for activation, is seen for the agonists, nicotine, ACh, cytisine, epibatidine, A85380, varenicline and compounds 1, 2 and 10. In contrast, antagonists that have highest affinity for a4b2*-nAChR also have highest potency for inhibition at that subtype. In addition, compound 8 has no functional activity at a6b2*-nAChR, so it cannot be compared. ing the relatively lower affinities measured for a6b2* sites using a-CtxMII, an antagonist. Therefore, we compared data collected by two independent methods for binding to a6b2*-nAChR sites to check accuracy of the results of this screening method. The first method, illustrated in Fig. 2D, is . In addition, the a4 subunit null mouse has w50% lower [ 125 I]-a-CtxMII binding in these regions, although the affinity for a-CtxMII is unchanged (Salminen et al., 2005 (Salminen et al., , 2007 . In a comparison of K i values determined by the two methods Grady et al. (2001) . c From Marks et al. (1999) . Compound 11 À100 AE 9% À100 AE 6% À100 AE 18% 31 AE 12% 8 AE 2%
In this representation, negative numbers signify antagonists and % values are for maximum inhibitory effect on nicotine-stimulated activity. Positive numbers are agonists and values represent maximum effect as compared to nicotine. Nicotine response at 10 mM was defined as 100% for a4b2* and a6b2*-nAChRs, 30 mM was 100% for a3b4*, and for a7, 100% was at 200 mM nicotine and all were measured in the same experiments as the compound. All values are as maximal release or inhibition from curve-fits of the data. naa ¼ no agonist activity.
(see Table 1 for values AE sem for both methods for those compounds assayed both ways), the regression slope on logarithmic axes was 1.08 AE 0.08 with a correlation coefficient of 0.96 (Fig. 5B) . Furthermore, the mean ratio of the K i values determined by the two methods (0.88 AE 0.13) is not significantly different from 1. Therefore, we conclude that the lower affinity values measured for a6b2*-nAChR (Fig. 5B ).
a7-nAChR-mediated responses
All of the compounds tested, except Compound 9 which was inactive, showed at least some agonist activity for a7-nAChR-mediated function ( Fig. 4C and Table 3 ). Compound 2 is a full agonist. However, like Compound 1, the EC 50 value for this compound (4.97 mM) was significantly higher than the corresponding value observed for a4b2* (0.68 mM) and a6b2* (0.05 mM) responses. Compounds 3 and 5 are full agonists with EC 50 values of 0.15 and 4.1 mM, respectively. Partial agonist activity was noted for the remaining compounds with efficacies ranging from 17% to 63%. In general, EC 50 values for a7-nAChR activation were markedly higher than those for a4b2*-and a6b2*-nAChR mediated responses, although the ratio of EC 50 to K i value (77 AE 14, n ¼ 11) was similar to that for a4b2*-nAChR. (Fig. 4C and Table 3 ). Compounds 1, 2, 3, 4, 5 and 7 were full or nearly full agonists, while Compounds 8, 10 and 11 were partial agonists. The EC 50 for Compound 8 was a very high 218 mM. Both Compound 6 and Compound 9 were full antagonists, with Compound 6 exhibiting high potency (K I ¼ 0.66 mM).
Evaluation of effect of structural differences on interaction with nAChR subtypes
Compound 8 and Compound 9 are both classified as metanicotines, analogs of nicotine in which the pyrrolidine ring is opened and a double bond introduced adjacent to the pyridine. This results in a more flexible molecule than nicotine and increases the distance from the cationic center to the hydrogen bond acceptor. Relative to nicotine, Compound 8 possesses decreased affinity at a4b2*, a7 and a6b2* subtypes. Like nicotine, Compound 8 displayed selectivity for the a4b2* subtype, consistent with previous reports (Bencherif et al., 1996) . In terms of functional activity, Compound 8 is even more efficacious than nicotine at a4b2*, but displays no measurable activity at a6b2* and weak partial activity at a3b4* and a7-subtypes.
Introduction of a phenyl ring at the 5 0 position of the pyridine (Compound 9) through an alkyne linker further reduced binding affinity across subtypes, but maintained selectivity for the a4b2* sites. This modification also resulted in antagonism at all subtypes, though antagonism at a6b2* was partial (w50% inhibition). It remains to be seen whether this compound selectively inhibits one of the complex a6b2*-nAChR subtypes (i.e., a6* receptors with or without an a4 subunit incorporated).
Constraining the basic structural elements of Compound 8 (pyridine, alkene, aminomethyl) into an azabicyclo[3.2.1]octene ring and adding a 5 0 -bromo substituent results in Compound 10. This conformational constraint increased the binding affinity by more than an order of magnitude at all four subtypes, while still retaining modest selectivity for a4b2*. These modifications also returned partial agonist activity at all subtypes measured. In fact, Compound 10 appears unique among the compounds studied here in having partial agonist activity across all subtypes. Relative to Compound 8, Compound 10 exhibited significantly reduced efficacy (25% of Compound 8) at both a-CtxMII-resistant DA release and a4b2*- based functional selectivity (w100-fold) for the b2* (both a4 and a6) containing subtypes over both a7 and a3b4*-subtypes. This selectivity might be expected to reduce side effect liabilities relative to less selective ligands, particularly with regard to the a3b4* subtype.
Replacement of the pyrrolidine ring of nicotine by the azabicyclo [2.2.2]octane (quinuclidine) ring system (Compound 1) has multiple steric and electronic effects. The basicity of the cationic center nitrogen is greatly enhanced, steric bulk around the cationic center is also greatly increased, and the resulting molecule is considerably more rigid. These structural modifications conferred enhanced binding affinity across all four receptor subtypes (w10e40efold increase). With respect to efficacy and potency, Compound 1 is The Compound 1 template was further elaborated at the 5 0 -pyridine position, to explore the effects of aromatic bulk across the various receptor subtypes. Introduction of a phenyl ring gave Compound 6, which exhibited decreased affinity for all four subtypes (Fig. 4A and Table 1 ). This decrease was modest (w4e5efold) for a4b2* and for a6b2*, but approximately 10-fold for a3b4*. The largest effect was noted for the a7 subtype, where affinity decreased approximately 50-fold. The presence of the phenyl ring markedly affects functional activity for several subtypes. Agonism was abolished at a4b2* or a6b2*, resulting in full, potent antagonists. Compound 6 was also a full antagonist at a3b4*, but retained weak partial agonist activity at a7 (18% E max , 29 mM).
Extension of the 5 0 -position of Compound 1 with a 4-cyanophenoxy group provided Compound 7. This modification was quite well tolerated, retaining affinity comparable to that of the parent Compound 1 for a4b2*, a6b2* and a7 subtypes, while decreasing affinity for the a3b4* subtype by w10-fold. Like Compound 6, Compound 7 was a potent, full antagonist at a4b2* and a6b2*. In fact, at a6b2* it was 40 times more potent than Compound 6. At a3b4* and a7, the agonism profile more closely matched that of parent Compound 1, with full agonism at a3b4* and partial at a7 (103% and 63%, respectively).
Compound 5 and Compound 11 both retain the azabicyclo[2.2.2] octane ring of Compound 1, but extend the pyridine group away from the basic nitrogen by a carbon or one carbon and one oxygen atom, respectively. For Compound 5, the affinity was markedly decreased at all four sites relative to Compound 1. The smallest change was observed for a7 (w7-fold reduction), while the a6b2* affinity decreased 80-fold. Compound 5 was a full antagonist at both a4b2* and a6b2*-subtypes while maintaining full but less potent agonism at the a7 and a3b4*-subtypes.
Additional extension of the methylene spacer by introduction of an oxygen atom and translocating the spacer from the 2-to the 3-position on the quinuclidine yielded Compound 11 (which also has a 5 0 -Cl substitution in the pyridine ring). This further reduced affinity at all four binding sites compared to Compound 5 (further 7-to 26-fold decrease). Similar to Compound 5, full antagonism was observed at a4b2* and a6b2*, but potency was reduced somewhat (16 and 2-fold, respectively). Surprisingly, a loss of agonism was observed at both a7 and, more profoundly, a3b4* (E max ¼ 31% and 8%, respectively). We cannot yet distinguish the individual contributions of the 5-chloro substituent and the oxygen atom relative to the increase in linker length alone, because the corresponding analogs were not available for evaluation.
A one-carbon reduction in the bridging ethyl group of Compound 1 afforded the corresponding 1-azabicyclo[2.1.1]heptane (Compound 2). This resulted in markedly reduced binding affinity for all four sites: w20-fold at a4b2*, a6b2* and a3b4*. Compound 2 did retain agonism at the a6b2*, a7 and a3b4* subtypes as well as partial agonism at a4b2*, but was less potent than Compound 1. Compound 2 also retained the full, potent agonism at a6b2* observed for Compound 1 (114%, 0.050 mM), and the a6b2* functional selectivity is even higher due to the reduced potency at a4b2*-subtype. Finally, addition of two carbons to the Compound 1 ring system and altering the bridge connectivity produced the highly constrained 1-azatricyclo [3.3.1.13,7] decane (aza-adamantane), Compound 4. The binding affinity of Compound 4 was markedly reduced across all subtypes, quite similar to the profile observed for Compound 2. The increase in steric bulk surrounding the cationic center apparently resulted in full antagonism of a4b2*. At the a6b2* subtypes, full antagonism was also observed, in contrast to the partial antagonism of Compound 3. Compound 4 exhibited a reduction of efficacy and large loss of potency at a3b4* and a7 (88%, 34 mM and 27%, 8.5 mM, respectively). This efficacy-potency shift again affords a selective antagonist.
The potency is highest for a4b2* (0.069 mM), with some antagonism for a6b2* (0.57 mM), and less at a7 (34 mM) and a3b4* (8.5 mM).
Evaluation of effects of compounds in vivo
In order to assess the effects of selected compounds in vivo, we used mice with gain-of-function mutations in a4 and a6 subunits. Mice with the a4L9 0 A or a6L9 0 S mutations respond to very low concentrations of nicotine that have no measurable effect in wild type mice and allow an assessment of whether a compound is bioavailable as well as whether it activates or inhibits a specific subtype of nAChR in vivo. For the a4L9 0 A mice, injection of 0.03 mg/kg nicotine produces a 3 C temperature decrease, while this dose elicits no hypothermia in wild type mice (Tapper et al., 2007) . Thus this procedure measures an effect of nicotine restricted to the a4*-nAChRs. For the a6L9 0 S mice, low doses of nicotine (0.02e0.15 mg/kg ip) result in locomotor activation (w350% of saline activity for 0.15 mg/kg nicotine), while in wild type there is no effect of these doses of nicotine, and, in fact, higher doses (0.5e2.0 mg/kg ip) in wild type mice as well as doses over 1 mg/kg in a6L9 0 S mice produce locomotor suppression (Drenan et al., 2008) . In addition, the a6L9 0 S-gain-of-function mice have the same temperature depression responses as wild type mice (unpublished data; see Tapper et al., 2007 for wild type), <1 C temperature decrease with a dose of 0.1 mg/kg nicotine. Thus, this measurement isolates an a6*-nAChRmediated physiological effect. Representative experiments using Compound 1, identified as a partial agonist at a4b2* and a full agonist at a6b2* in the in vitro assays are shown in Fig. 6 . Compound 1 proved active in vivo and stimulated both a4L9 0 A* nAChRs, with 0.03 mg/kg inducing w8 temperature drop and a6L9 0 S*-nAChRs where 0.01 mg/ kg resulted in w290% increase in activity over saline. Subsequently, the agonists Compounds 2, 8 and 10 were evaluated for their ability to elicit hypothermia or locomotor activation in a4L9 0 A and a6L9 0 S mice. As shown in Table 4 , each of these compounds elicited responses in both mutant mice expressing hyperactive nAChR. Compounds 3, 4 and 7, which were identified as antagonists, blocked the effects of 0.1 mg/kg nicotine in vivo. Data for nicotine and varenicline are provided for comparison in Table 4 .
Discussion
The CNS nAChRs have various roles in normal brain function. These receptors are activated by the natural neurotransmitter, acetylcholine, and their activity may also be modified by the presence of nicotine (Perez et al., 2008) . Nicotine from tobacco smoking occupies a large fraction of the a4b2*-nAChR (Brody et al., 2008) . Such data are not available for the a6b2*-nAChRs, but if nicotine occupies a lower percentage of these receptors, or desensitizes them less readily, nicotine use could produce an altered balance between GABAergic and dopaminergic function. To better understand the role of the a6b2* and to define the optimal profile for therapeutics targeting nicotine addiction as well as other disorders that are potential targets for nicotinic receptor-based therapy, selective ligands are necessary. The lack of available data around a6b2* SAR and limited structure-function data for other subtypes led us to prepare and/or characterize a number of known and novel ligands across various nicotinic receptor subtypes.
Our data show that commonly studied nicotinic agonists including nicotine, acetylcholine, cytisine and A-85380, bind to a4b2*-nAChR subtype with higher affinity than to a6b2*, and, generally, had lower affinity at both the a7 and a3b4*-subtypes (see Fig. 4A and Table 1 ).
However functional measurements ( Fig. 4B and Table 2 ) reveal that several agonists activate a6b2*-nAChR at lower concentrations than a4b2*-nAChR. Thus, the relationship between binding affinity and functional potency differed markedly between the a6b2*-and a4b2*-nAChRs (see also Salminen et al., 2005) . Presumably this disparity arises from inherent differences in relationships among binding, activation and desensitization. Further study will be required to understand this topic. Furthermore the a6b2*-subtype actually comprises several receptors, including a4a6b2b3, which is activated by lower concentrations of nicotine than the a6b3b2 or the a4(nona6)b2*-nAChR (Salminen et al., 2007) .
Varenicline (currently marketed as a smoking cessation aid) was also evaluated in our assays. We found that varenicline is a partial agonist at both a4b2* and a6b2*-nAChRs, but a full agonist at both a7 and a3b4* subtypes; these conclusions (for a4b2*, a7 and a3b4* subtypes) agree with data from oocyte-expressed nAChRs (Mihalek et al., 2006) and from rat brain slices (Rollema et al., 2007) . Note that the structurally-related compound cytisine, is also a partial agonist at a4b2*-nAChRs (37%); however, cytisine is more efficacious at a6b2* (71%) (Salminen et al., 2004) . For varenicline, efficacy is not significantly different between these subtypes for this screen (26 AE 2% and 39 AE 17%, respectively). We found an w8-fold ratio of EC 50 values between a7 and a4b2*-subtypes, the same as previously reported for oocyte-expressed receptors (Mihalek et al., 2006) . According to our data in mouse tissue, varenicline is somewhat selective for a4b2*-nAChR when assessed with binding affinity (2-fold over a6b2*, 9-fold over a7 and 24-fold over a3b4*) though considerably less selective than reported for rat brain a4b2* compared to a7 in IMR32 cells (Rollema et al., 2007) . Our data on varenicline generally agree with published data from other laboratories (see Supplementary Table 1 for a compilation of data with species, method and source) in finding that it is a partial agonist at a4b2*, with higher efficacy at a7 and a3b4*-nAChR. There may be some species or methods differences in these data.
The structures of a series of nicotine-related compounds that were evaluated in this study are shown in Fig. 1 . Within this series, the basic pharmacophoric elements of nicotine (cationic center, hydrogen bond acceptor and aromatic ring) were retained, but elaborated into a set of chemically diverse analogs: 1) the distance from the pyridine to the cationic center is varied, 2) steric bulk of the molecule (particularly the region around the cationic center) is explored, and 3) flexibility is varied from compounds with many degrees of freedom (the metanicotines Compounds 8 and 9) to highly constrained (3-pyridinylazatricyclo[3.3.1.13,7] decane) Compound 4. Some data on affinity, potency and efficacy have been previously published for certain of these compounds and a comparison of these values, along with species and references, is presented in Supplementary Table 2 . As with varenicline, some differences may result from methods or species used. Despite the wide variety of techniques and species, there is considerable agreement where comparable data exist.
The data presented here suggested several observations about the role of structure in affinity and efficacy. Generally, constraining the cationic nitrogen into certain ring variations enhances affinity across all subtypes relative to the open-chain metanicotine. Increasing the conformational constraint further by capturing the cationic center into bicyclic ring systems further enhances affinity. This affinity enhancement is illustrated clearly in the progression from Compound Locomotor activation assay in a6L9 0 S mice to assess bioavailability and in vivo activity at a6b2* nAChRs. Average locomotor activity (n ¼ 8 mice) for a6L9 0 S and WT control mice is shown in response to an i.p. injection of Compound 1 (0.01 mg/kg). All data shown are means AE sem. Table 4 Physiological effects in mice with hypersensitive a4b2* or a6b2*-nAChR. For example, the cationic center is changed from secondary to tertiary, basicity is increased, lone nitrogen electron pair orientation altered, steric bulk is added (which can be both repulsive or provide positive hydrophobic interactions), and bond distances and orientation are all altered. Increasing the distance between the pyridine nitrogen and the cationic nitrogen also appears to greatly reduce affinity across all subtypes. This is qualitatively observed in comparing the properties of nicotine to those of Compound 8, and the properties of Compound 1 to those of structurally related azabicylics, Compounds 5 and 11. Comparing efficacy trends within the range of structures examined, here we noted that agonist activity is more readily retained for both the a7 and a3b4*-nAChR subtypes than the a4b2* and a6b2*-nAChR subtypes. This suggests that the binding pockets of the latter subtypes have stricter structural requirements for activation than the former. For example, in the series of Compounds 2, 1, 3 and 4, the azacyclic portion of the molecule is made progressively more sterically demanding. Functional activity at a4b2* shifts to partial agonism and antagonism across the series (43%, 30%, À97%, À100% efficacy compared to nicotine, Fig. 4C and Table 3 ). Efficacy at the a6b2*-nAChR subtype appears slightly more tolerant of structural modifications to its ligands relative to the a4b2*-nAChR. Here, the decrease in efficacy is more gradual within the series (114%, 109%, À71%, À98%). In contrast, at a7 and a3b4*, these same compounds all retain agonism, with very gradually decreasing efficacy (respective efficacy for a7, 108%, 89%, 106%, 27%; for a3b4*,118%, 106%, 95%, 88%).
In vitro functional assays for a4b2*-and a6b2*-mediated responses identified the reference compounds, nicotine and varenicline, as full and partial agonists, respectively. Consistent with this identification, both of these compounds induced hypothermia in a4L9 0 A and locomotor hyperactivity in a6L9 0 S hypersensitive mice. Likewise, Compounds 1, 2 and 10, identified as full or partial a4b2* and a6b2* agonists in vitro, elicited hypothermia and locomotor activation in mice expressing hypersensitive nAChRs (Table 1) .
Compound 8 with high efficacy at a4b2* also induced hypothermia in a4L9 0 A mice. Though this compound displayed no measurable activity at a6b2*-nAChR in WT mice in vitro, it did elicit a response in a6L9 0 S mice, consistent with its agonist activity in vitro in tissue from these mutant mice (Drenan et al., 2008) . Compounds 3, 4 and 7, which were identified in vitro as a4b2* and a6b2* antagonists, blocked the effects of nicotine in vivo, supporting the premise that they are, indeed, bioavailable antagonists. Results with these agonists and antagonists show that they effectively elicit the expected behavior in mice expressing the mutated receptors. However several compounds identified as antagonists in vitro (Compounds 5, 9, and 11) did not have intrinsic activity, nor did they block the effect of nicotine at the doses tested. In the absence of data on bioavailability, it is not possible to determine whether the lack of effect was receptor-based or, more likely, due to low concentration in the brain.It should be emphasized that these mice were designed to respond to agonists at doses much lower than the doses required for wild-type mice, so that a4* and a6*-dependent behavioral responses can be studied in the absence of effects on other AChRs. The hypersensitive mutations are located in the M2 transmembrane domain, some 60 Å from the agonist binding site. Thus while the present in vivo data serve well for a qualitative assignment of agonist vs. antagonist, the dose dependence in vivo is not relevant to the wild type nAChRs. In addition, correlation between the EC 50 values measured in vitro and the effective concentrations in vivo cannot be accurately assessed since potential differences in pharmacokinetics, metabolism and distribution leading to different exposures have not been taken into account. The functional characterization reported here has allowed us to achieve an important goal for this project, namely, the identification of an agonist selective for the a6b2*-receptor. Both Compounds 1 and 2 fulfilled the requirement for functional selectivity for a6b2* over a4b2*, a7 and a3b4* subtypes, although greater binding selectivity might be desirable. Additionally, both compounds exhibited in vivo activity consistent with their in vitro profiles. Major questions remain in the design of a safe and effective smoking cessation aid. Which natural functions of nicotinic systems must be preserved to avoid unwanted effects? What minimum level of occupancy is effective for a smoking cessation aid? Is a short-acting agent with high occupancy administered frequently better than one with a long half-life and low occupancy? Is it more effective to activate receptors, to desensitize them, or to chaperone them within intracellular compartments (Lester et al., 2009) ? Will selectively targeting a6b2*nAChR prove advantageous relative to other individual or multiple subtypes? Availability of relatively selective, bioavailable compounds such as Compound 1 and 2 or compounds designed on the SAR data reported here may enable research to help answer these questions.
